Nearly half of women experience hormone-driven vocal changes during menopause, which may alter voice quality and affect those in voice-reliant careers, a new review finds.

Former CDC director Susan Monarez, Ph.D., testified at today’s Senate hearing that HHS Secretary Robert F. Kennedy Jr. directed her to fire scientists for refusing to rubber-stamp vaccine changes.

Povorcitinib shows promising results for hidradenitis suppurativa, offering significant lesion reduction and pain relief in recent phase 3 trials.

Gen Z is most at risk for skin cancer due to a lack of knowledge about the sun and how to protect themselves.

Parents express mixed feelings about COVID-19 vaccines, revealing a significant divide in trust and safety perceptions, according to a KFF survey analysis.

Advances in HIV medication, its window of detection and its transmission risk within the last decade have led to an updated version of the HIV exposure protocol for healthcare personnel.

Elevated levels of the gut hormone GLP-1 and its receptor may worsen brain inflammation and trigger severe symptoms in patients with neuromyelitis optica spectrum disorder (NMOSD), suggesting GLP-1 drugs could pose risks for this rare autoimmune disease.

A half-dozen takeaways from an MJH Life Sciences webinar on the Trump administration's push for most-favored nation drug pricing

Providers also have concerns about being able to stock certain medications, which would have a negative impact on their patients, according the Avalere Health survey.

Using heart rate variability as a potential biomarker for diagnostic support and early screening of schizophrenia and bipolar disorder could eventually lead to faster, less costly assessments outside of clinical settings that would be especially helpful in rural areas and low-income countries, according to a study.

A recent study revealed that hidradenitis suppurativa affects 1% of the global population, highlighting significant gender disparities and the need for further research.

Results show that GLP-1s may address rheumatoid arthritis (RA) symptoms, independent of established weight loss and cardiac benefits, by reducing the systemic, chronic inflammation associated with RA.

New research uncovers how cancer-induced nerve injury drives resistance to anti-PD-1 therapy, revealing potential strategies to enhance treatment efficacy.

The NIH is funding a new study at Weill Cornell that aims to identify the regulatory roles of gene variants involved in Type 1 diabetes development.

Here’s what you missed this week on Managed Healthcare Executive.

Jennifer Walsh of George Washington University’s School of Nursing warned that limiting COVID-19 vaccine approvals to older adults and high-risk groups could heighten disparities, reduce access and leave vulnerable populations at greater risk of infection and severe outcomes.

Illuminate Rx is the country’s first pharmacist-designed pharmacy benefits optimizer (PBO), offering transparent, clinically driven PBM options for brokers and self-funded employers, with a focus on data clarity, flexible formulary design and specialty pharmacy partnerships, according to Robert Gamble, CEO of RxBenefits.

Previous research has shown the recombinant zoster vaccine is more effective than its live-attenuated predecessor, but new adverse event data show it also stands up well in terms of safety.

Ocaliva, approved for primary biliary cholangitis, faced FDA warnings and restrictions after postmarket data showed higher risks of liver transplant and death among treated patients.

Diagnosed with triple-negative breast cancer at age 36 and now in remission, Deanna Gerber, M.D., gynecologic oncologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital, says her experience has made her a better physician and advocate for her patients.

Discover groundbreaking research on hard-to-treat skin conditions like hidradenitis suppurativa and vitiligo at the EADV 2025 Congress in Paris.

A decline in PrEP coverage could reverse HIV prevention gains, causing tens of thousands of preventable infections and billions in added healthcare costs, a new JAMA Network Open study finds.

CT-155, an AI-powered smartphone app, addresses an unmet need in schizophrenia, showing safety and efficacy in a phase 3 trial.